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1. INTRODUCTION {#ajmgb32700-sec-0001}
===============

Effective treatments for depression remain elusive because of poor understanding of the underlying etiology of this highly prevalent disorder. Electroconvulsive therapy (ECT) is the treatment of choice for severe and treatment‐resistant forms of depressive episodes (Fink & Taylor, [2007](#ajmgb32700-bib-0010){ref-type="ref"}) and thus, patients assigned to ECT represent a specific subgroup selected for these factors. There is increasing evidence that severity of psychiatric disorder is associated with a higher genetic burden for the disorders, for example, (Amare et al., [2018](#ajmgb32700-bib-0002){ref-type="ref"}; Frank et al., [2015](#ajmgb32700-bib-0012){ref-type="ref"}). Recently, this has also been demonstrated in the largest genome‐wide association study (GWAS) for depression to date (Wray et al., [2018](#ajmgb32700-bib-0021){ref-type="ref"}) which showed that major depression is a highly polygenic disorder, that is, a result of the contribution of many genetic variants. Polygenic risk score (PRS) profiling is an approach that uses the risk variants and corresponding effect sizes identified in large GWAS such as the above study as a "discovery sample" to generate risk scores in an independent "target sample," reflecting the disease risk burden of each individual (Wray et al., [2014](#ajmgb32700-bib-0020){ref-type="ref"}). Presently, the clinical utility of PRS remains limited at the level of the individual as they only explain a small share of variance in case--control status or symptom severity. However, they can be used as a research tool to dissect disease aetiology by investigating the association of genetic risk burden for a disorder with related subphenotypes. In Wray et al. [2018](#ajmgb32700-bib-0021){ref-type="ref"}, higher PRS were associated with measures of increased severity such as early age at onset, symptom counts, and recurrent episodes (Appendix [\[Link\]](#ajmgb32700-app-0001){ref-type="app"}).

In the present study, we hypothesized that as ECT patients represent a severe and treatment‐resistant share of all MD patients, they should show an increased genetic burden for MD. We aimed to assess the feasibility of this approach to detect increased genetic risk of depression in a group of inpatients (*n* = 52) assigned to ECT as compared to population‐based controls. We generated PRS using results from the MD‐GWAS by Wray et al. ([2018](#ajmgb32700-bib-0021){ref-type="ref"}) (PGC‐MD2, Cases: *n* = 59,851; Controls: *n* = 113,154), testing whether these PRS were associated with MD ECT case--control status. In addition, we explored MD‐PRS in population based subjects with self‐reported MD, and MD‐PRS associations with clinical parameters in the ECT group.

2. MATERIALS AND METHODS {#ajmgb32700-sec-0002}
========================

This study was approved by the ethics committee (II) at the Medical Faculty Mannheim, University of Heidelberg. All patients provided written consent. All procedures were performed in accordance with the Declaration of Helsinki.

2.1. ECT patients {#ajmgb32700-sec-0003}
-----------------

Patients were recruited between 2014 and 2016 at the Department of Psychiatry and Psychotherapy of the Central Institute of Mental Health, Mannheim. Inclusion criteria were a present major depressive episode within the context of a diagnosis of either major depressive disorder or bipolar disorder according to DSM‐IV, age above 18 years and the clinical decision for an ECT treatment. Exclusion criteria were any substance‐related disorders, except tobacco and alcohol use. All participants were of Caucasian descent.

The criteria for assigning patients with a depressive episode to ECT were either treatment‐resistant depression defined as failure of two adequate dose‐duration antidepressants or psychotherapy from different classes in the current episode (Conway, George, & Sackeim, [2017](#ajmgb32700-bib-0007){ref-type="ref"}) or positive experience to ECT from a previous episode, or severe depression with (a) psychotic symptoms, (b) severe suicidality, or (c) the refusal of food or fluid intake.

A total of 52 inpatients consented to participate in the present study. In 36 of the 52 included patients (69.2%) the indication for ECT was a current treatment‐resistant depressive episode. Six patients (11.5%) with a current depressive episode were assigned to ECT because of positive experience to ECT during a previous depressive episode, whereas five (9.6%) other patients received ECT because of depression with severe psychotic symptoms. In three patients (5.8%), the severe suicidality that was accompanied by the depressive episode was the main indication for ECT and in two patients (3.9%) the indication was refusal of food and fluid intake. In three cases, a legal guardian gave the formal consent to the study for the patient. All other patients gave their consent on their own.

A comorbid personality disorder (PD) was indicated when already diagnosed prior to the recent depressive episode. Generally, that diagnosis was either given after a Structured Clinical Interview for DSM‐IV Axis II Disorders (SCID‐II) interview, but in some patients based on a clinical judgment. Out of the fifteen patients with comorbid PDs, there were seven patients with Borderline PD (46.7%), three patients with a dependent PD (20.0%), two patients each with a histrionic (13.3%) and avoidant PD (13.3%), respectively and one patient with an obsessive--compulsive PD (6.7%).

Of 52 patients, 7 discontinued the treatment prematurely after one of the initial ECT sessions: four patients discontinued ECT after the first (*n* = 2), second (*n* = 1), or third (*n* = 1) session because of subjective intolerable side effects; one patient left the hospital against the medical advice after the fourth ECT session; in one patient ECT was stopped after suffering from a serotonergic syndrome because of ECT and concomitant medication; one patient dropped out due severe hyponatremia during the course of treatment and subsequent transfer to a hospital for internal medicine. Furthermore, we excluded one patient with diagnosis of schizophrenia from statistical analyses.

2.2. Controls {#ajmgb32700-sec-0004}
-------------

Data from Heinz Nixdorf Recall (HNR) study, a population‐based study of individuals with homogeneous German ethnicity, comprised the control sample (*n* = 4,814, M:2395; F:2419). The HNR controls had been assessed for depression status using a computer‐assisted personal interview with the question: "Do you have or have you ever had depression? (Y/N)". A total of *n* = 3,547 answered "no" and *n* = 426 answered "yes", whereas answers for *n* = 841 were unknown.

2.3. Assessments {#ajmgb32700-sec-0005}
----------------

ECT patients were assessed for demographics, including: Age, sex (male/female) and body mass index.

Baseline clinical factors were also assessed: age at first disease onset, length of current episode (months), multiple drug therapy resistance (yes/no), presence of PD (yes/no), positive family history in first degree relatives for affective disorders (yes/no), type of depression (unipolar or bipolar depression), alcohol dependence or abuse (yes/no), and nicotine dependence (yes/no).

The 21‐item version of the Hamilton depression rating scale (HDRS) was administered pre‐ and post‐ECT treatment.

2.4. ECT {#ajmgb32700-sec-0006}
--------

Right unilateral brief pulse ECT was performed with a Thymatron IV device (Somatics, LLC. Lake Bluff, IL). S‐ketamine (\~1.0 mg/kg) or thiopental (\~5 mg/kg) were used as anesthetic agents and succinylcholine (\~1.0 mg/kg) for muscle relaxation. Seizure threshold was titrated at the initial session and stimulation dose at subsequent treatments was given at above 2.5 times the seizure threshold (Bumb et al., [2015](#ajmgb32700-bib-0005){ref-type="ref"}; Hoyer et al., [2017](#ajmgb32700-bib-0013){ref-type="ref"}). Charge was subsequently adjusted if seizures were considered as potentially insufficient during the ECT course (e.g., motor response time \<15 s or electroencephalogram (EEG) seizure activity \<25 s; Kranaster, Hoyer, Janke, & Sartorius, [2013](#ajmgb32700-bib-0016){ref-type="ref"}).

The psychiatrist, who was responsible for the whole in‐patient treatment of the respective patient, made the clinical decision of when to terminate the ECT course. ECT was continued until the subject showed either a remission or a stable response or did not show a significant response after at least 12 ECT sessions. In the case of no further and relevant clinical improvement for 2 weeks (4--6 ECT sessions), ECT was terminated.

No specifications on the concomitant psychotropic medication were made.

2.5. Blood sampling, control data, genotyping and quality control {#ajmgb32700-sec-0007}
-----------------------------------------------------------------

A venous blood sample was collected from participants for genome‐wide genotyping. Genotyping was performed using the Global Screening Array (Illumina, Inc., San Diego, CA). The HNR sample had also been genotyped using the Global Screening Array. The merged data set contained *n* = 642,553 overlapping SNPs. The data were subjected to a stringent quality control (QC) procedure, which included following parameters for retainment in data set: SNP missing rates \<0.05 (prior to filtering individuals), individual missingness \<0.02, autosomal heterozygosity deviation \|*F* ~het~\| \< 0.2, SNP missing rate \< 0.02 (after filtering individuals), minor allele frequency \> 0.01, Hardy--Weinberg equilibrium (Case: *p* \> 1e^−10^, Control: *p* \> 1e^−6^, Overall: *p* \> 1e^−6^) and difference in missing rate between cases and controls \<0.02. Ten principal components (PCs) were computed using principal component analysis (PCA) on a filtered subset of frequent (MAF \> 0.05) autosomal SNPs in approximate linkage equilibrium (pairwise *R* ^2^ \< 0.1 within a window of 250 SNPs) to find informative ancestry information and detect and remove genetic outliers (defined as those exceeding six standard deviations). A relatedness cutoff of Pi Hat = 0.125 was used to exclude related individuals. Filtering was performed using PLINK 1.90 (Chang et al., [2015](#ajmgb32700-bib-0006){ref-type="ref"}). After QC, the data set comprised 44 ECT cases and 4,290 individuals from the HNR sample, with 485,607 variants remaining. Of the HNR individuals passing QC, *n* = 376 had self‐reported depression (HNR‐DEP) and *n* = 3,172 were healthy controls. Those with unknown depression status (*n* = 742) were removed from the analysis.

2.6. Data analysis {#ajmgb32700-sec-0008}
------------------

Statistical analyses were performed using IBM SPSS Statistics for Windows version 24. Descriptive statistics were calculated for all participants.

Given the sample size and uneven proportion of responders/nonresponders, we calculated nonparametric Spearman\'s rank correlations to examine factors related to response. Response was examined categorically (yes/no), defined as a 50% reduction in HDRS scores, and also a continuous variable (ΔHDRS score, the pre‐post difference between HDRS). Correlations with remission, defined as post‐treatment HDRS score \> 10, were also examined.

2.7. Polygenic risk score calculation {#ajmgb32700-sec-0009}
-------------------------------------

PRS were calculated using genome‐wide association data from the Psychiatric Genomics Consortium (PGC‐MD2, Cases: *n* = 59,851; Controls: *n* = 113,154)(Wray et al., [2018](#ajmgb32700-bib-0021){ref-type="ref"}) using PRsice v 1.25 (Euesden, Lewis, & O\'Reilly, [2015](#ajmgb32700-bib-0009){ref-type="ref"}). Clumping was carried out to retain only one representative variant per region of linkage disequilibrium (LD) using thresholds of p1 1, p2 1 an LD threshold of *r* ^2^ ≥ 0.1 and a distance threshold of 500 kb. The multi histocompatibility complex of chromosome 6 was excluded. Scores were calculated for a range of *p*‐value thresholds (5 × 10^−8^, 1 × 10^−6^, 1 × 10^−4^, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5, 1.0). PRS were standardized to the mean and standard deviation of controls, that is, . (PRS − mean~controls~)/standard deviation~controls~ (Lewis & Vassos, [2017](#ajmgb32700-bib-0017){ref-type="ref"}).

A binomial logistic regression analysis was carried out to determine the contribution of MD‐PRS to disease status. Case--control status was specified as the dependent variable. Proportion of variance explained by PRS was tested by comparing Nagelkerke\'s *R* ^2^ in an initial model including PCs informative of case--control status to a full model which additionally included PRS. Data from HNR‐DEP were not included in the case--control analysis.

In a next step, we included HNR‐DEP individuals passing QC (*n* = 376) and calculated PRS. Using the above method, binomial regression analyses were used to compare both ECT vs. HNR‐DEP and HNR‐DEP vs. controls.

Using partial correlations (accounting for PCs informative of case--control status), we tested whether MD‐PRS were correlated with ECT response and demographic/clinical factors in the ECT sample.

3. RESULTS {#ajmgb32700-sec-0010}
==========

3.1. Descriptive statistics {#ajmgb32700-sec-0011}
---------------------------

Descriptive statistics are shown on Table [1](#ajmgb32700-tbl-0001){ref-type="table"}.

###### 

Descriptive and clinical statistics of ECT patients

  Descriptives                     Total (*n*)   Mean (*SD*)                            
  -------------------------------- ------------- -------------------------------------- ----
  Age, years                       45            58.38 (18.722)                         
  Body mass index                  38            25.71 (4.165)                          
  Age at initial disease onset     38            41.29 (19.324)                         
  Current episode length, months   37            11.38 (12.722)                         
                                                 Yes                                    No
  Sex (male/female)                45            22                                     23
  Alcohol use disorder             42            6                                      36
  Tobacco                          42            12                                     30
  Positive family history          38            19                                     19
  Personality disorder             38            15                                     23
  Response                         37            30                                     7
  Remission                        37            14                                     23
  HDRS baseline                    42            27.26 (6.356)                          
  HDRS final                       38            10.58 (6.832)                          
  Diagnosis                        52            MDD: 32 (7 excluded), BD: 12, SCZ: 1   
  Bilateral ECT                    45            8                                      37

The correlation analysis revealed that categorical response (50% reduction in HDRS) was statistically significantly correlated with being male (rho = 0.332, *p* = .045, df = 35), having a positive family history for affective disorders (rho = 0.358, *p* = .029, df = 35), and negatively correlated with diagnosis of PD (rho = −0.335, *p* = .043, df = 35). Tobacco use was negatively correlated with response (rho = −0.290, *p* = .082, df = 35) at the trend level. No other variables showed statistically significant correlation with response.

Examining response as a continuous variable (ΔHDRS score) yielded similar findings with respect to male sex (rho = 0.373, *p* = .021, df = 36) and PD (rho = −0.335, *p* = .043, df = 35). Additionally, ΔHDRS score was associated with increased age (rho = 0.363, *p* = .001, df = 36), negatively associated with length of current episode (rho = −0.348, *p* = .035, df = 35 and positively correlated with increased age at first disease onset (rho = 0.370, *p* = .022, df = 36). No other variables showed statistically significant correlation with ΔHDRS score.

Remission was positively correlated with age (rho = 0.426, *p* = .009, df = 35), age at first disease onset (rho = 0.494, *p* = .002, df = 36), and at the trend level with having bipolar disorder (rho = 0.328, *p* = .051, df = 34).

3.2. PRS {#ajmgb32700-sec-0012}
--------

Although removed from the response analysis above, the genotype data from the dropouts were used in the PRS analysis as they still represent cases assigned to ECT.

For case--control status, a *p*‐value threshold of 1.0 was found to be the most informative threshold (see Figure [1](#ajmgb32700-fig-0001){ref-type="fig"}a). Statistically significantly higher PRS were found in ECT cases than controls (*p* = .022) (see Figure [1](#ajmgb32700-fig-0001){ref-type="fig"}b, left and right bar), explaining Δ~Nagelkerke~ *R* ^2^ = 1.173% of variance, using information from *n* = 83,066 SNPs.

![(a) Model fit for case--control status of MD‐PRS calculated at different *p*‐value thresholds. \**p* \< .05, \#*p* \< .10. (b) Standardized polygenic risk scores in: healthy controls (left, *n* = 172); individuals with self‐reported depression, (middle, *n* = 376); ECT patients (right, *n* = 44). Error bars denote standard error of mean](AJMG-180-35-g001){#ajmgb32700-fig-0001}

Descriptively, PRS scores in HNR‐DEP were intermediate to ECT patients and controls (see Figure [1](#ajmgb32700-fig-0001){ref-type="fig"}(b), middle bar). No statistically significant differences were observed between ECT patients and HNR‐DEP (*p* = .237), or HNR‐DEP and controls (*p* = .150).

In a partial correlation analysis we examined whether MD‐PRS differed in responders (coded 1) and nonresponders (coded 0) to treatment. A statistically significant correlation was not observed (rho = −0.189, *p* = .300, df = 30) but descriptively, the direction was for nonresponders to have higher PRS for MD than responders. The correlation between MD‐PRS and response coded as Δ HDRS score was also not statistically significant (rho = −0.016, *p* = .930, df = 31). A statistically significant correlation was observed between MD‐PRS and alcohol dependence/abuse (rho = 0.372, *p* = .023, df = 35), but no other demographic or clinical variables showed statistically significant correlations with MD‐PRS.

4. DISCUSSION {#ajmgb32700-sec-0013}
=============

The present feasibility study represents the first usage of a whole‐genome (PRS) approach in an ECT sample. Our findings using a multi‐marker technique to characterize an important subgroup of depressed patients show that patients assigned to ECT hold potential for further exploration using a molecular genetics approach. These patients are usually suffering from severe or therapy‐resistant forms of depressive episodes, which appears to be consistent with having an increased genetic burden of disease. Individuals from the HNR cohort self‐reporting depression had scores intermediate to ECT patients and controls, suggesting that although they indicated that they had depression, these individuals had less genetic burden of MD.

The ability of the PRS to predict case--control status, while small (*p* = .022, Δ~Nagelkerke~ *R* ^2^ = 1.173%), is similar to that of other studies using similar approaches in psychiatric genetics (on the order of 10^−2^ to 10^−3^, see also Wray et al., [2018](#ajmgb32700-bib-0021){ref-type="ref"}). Although not clinically informative at this stage, these results are consistent with depression being a polygenic trait and suggest the potential utility of the PRS approach to characterize patient subgroups in samples of larger size.

We did not observe statistically significant correlations between MD‐PRS and response. Descriptively, the direction was for nonresponders to have higher PRS, but conclusions cannot yet be drawn as our analysis was underpowered: because of the efficacy of ECT, the proportion of nonresponders is necessarily small, rendering statistical comparison a challenge, especially in a sample of the present size. Interestingly, we observed increased MD‐PRS in patients with a history of alcohol dependence/abuse, which is consistent with a large body of research describing comorbidity between depression and alcohol dependence at the clinical and genetic levels and supports recent reports suggesting that genetic pleiotropy may be responsible for this disease comorbidity (Andersen et al., [2017](#ajmgb32700-bib-0003){ref-type="ref"}; Foo et al., [2018](#ajmgb32700-bib-0011){ref-type="ref"}). In a recent study, we observed that alcohol use disorder is a positive predictor of ECT response (Aksay et al., [2017](#ajmgb32700-bib-0001){ref-type="ref"}). We did not find any such evidence in the current study, most likely because of the limited number of nonresponders and small proportion of patients with alcohol dependence/abuse. Caution is needed when generalizing these findings and confirmation in a larger sample awaits.

It is also worth mentioning that our finding that presence of comorbid PDs was negatively correlated with the antidepressant response to ECT corroborates previous data (de Vreede, Burger, & van Vliet, [2005](#ajmgb32700-bib-0008){ref-type="ref"}; Kaster, Goldbloom, Daskalakis, Mulsant, & Blumberger, [2018](#ajmgb32700-bib-0014){ref-type="ref"}; Rasmussen, [2015](#ajmgb32700-bib-0018){ref-type="ref"}).

With its short time course and striking therapeutic effects, ECT offers a good model to explore fundamental biological mechanisms (i.e., immunological, neurotrophic, epigenetic) underlying changes in depressive symptomatology observed as a result of treatment. Clinical findings about the role of genetic factors suggest a possible role in gene variation in the mediation of response to ECT (Kellner, Popeo, Pasculli, Briggs, & Gamss, [2012](#ajmgb32700-bib-0015){ref-type="ref"}); while supporting this idea, existing data remains preliminary, highlighting the need for large‐scale confirmatory studies (Benson‐Martin, Stein, Baldwin, & Domschke, [2016](#ajmgb32700-bib-0004){ref-type="ref"}). Investigations so far have only explored the candidate gene level and to go beyond "tentative knowledge," systematic genome‐wide studies which can identify unequivocally contributing genes are needed (Sullivan, [2017](#ajmgb32700-bib-0019){ref-type="ref"}).

Our study has several limitations. First, while ECT cohorts have the advantage of being well‐phenotyped and characterized, only severe cases are assigned, leading to necessarily limited sample sizes. The sample used in the current study, while large for an ECT sample, is limited when considered in the perspective of GWAS. On the other hand, GWAS studies often suffer from limited phenotyping at the expense of larger numbers to gain statistical power. Further investigations which tackle both of these issues and investigate well‐characterized, larger samples are expected to give the power needed to clarify underlying mechanisms. For example, even samples not deeply phenotyped but including health record information indicating that ECT was performed can be included.

Next, descriptively we found that population‐based individuals who had self‐reported depression had lower PRS for MD than patients assigned to ECT. It should be noted that the self‐report depression status is not equivalent to a clinical diagnosis, and this group is potentially heterogeneous. While it has been shown that self‐reports of depression carry enough signal to be reflected in genetics (e.g., Wray et al., [2018](#ajmgb32700-bib-0021){ref-type="ref"}), comparison to a sample of expert‐diagnosed patients with MDD/BD not undergoing ECT would offer more refined insight.

It should also be noted that our ECT cohort comprised both patients with MDD and BD. In a post‐hoc test, we examined whether or not this affected the results of the comparison of ECT patients and controls. After repeating the calculation with bipolar patients excluded, we found that results did not change substantially (*R* ^2^ = 1.228%, *p* = .037).

Here, we have shown the potential utility of a PRS approach to examine genetic risk for MD in patients assigned to ECT. It is important to move in the direction of taking advantage of ECT as a model to examine the etiology of antidepressant response as it provides a clear pre‐post treatment longitudinal design which can be investigated using time‐sensitive gene expression and epigenetic/epigenomic methods. Further research taking advantage of such a longitudinal design is expected to allow more in‐depth exploration into both phenotypic changes observed and the underlying biology and eventually will inform treatment strategies.
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